INTRODUCTION
============

The recent development of a radioreceptor assay for thyrotrophin has made it possible to detect immunoglobulins that inhibit the binding of thyrotropin to its receptor in some patients with autoimmune thyroid diseases^[@b2-kjim-2-1-112-19]^.

Although these immunoglobulins have been detected primarily in patients with Graves' disease, in whom their relation with thyroid stimulating antibodies has been extensively studied^[@b3-kjim-2-1-112-19]^, they have also been found in a small portion of hypothyroid patients with Hashimoto's thyroiditis^[@b2-kjim-2-1-112-19]--[@b10-kjim-2-1-112-19]^. These immunoglobulins, originally called thyroid-stimulating immunoglobulins by Smith and Hall^[@b2-kjim-2-1-112-19]^, are more appropriately termed thyrotrophin-binding inhibitor immunoglobulins^[@b4-kjim-2-1-112-19]^, and they are now considered to be autoantibodies to portions of the thyroid plasma membrane, including the thyrotrophin receptor^[@b3-kjim-2-1-112-19]^. In the present study, we investigated the activity of thyrotrophin binding inhibitor immunoglobulins in Graves' disease and various types of thyroiditis, and analyzed the clinical and laboratory features of patients who have these inhibitors.

PATIENTS AND METHODS
====================

Thirty patients with Graves' disease, 13 patients with Hashimoto's thyroiditis, 20 patients with LT-SRH, 5 patients with postpartum thyroiditis, and 7 patients with subacute thyroiditis (SAT) diagnosed inclusively between November, 1985 and October, 1986 have been studied ([Table 6](#t6-kjim-2-1-112-19){ref-type="table"}).

The diagnosis of Graves' disease was based on the following criteria: (1) Nervousness, profuse sweating, palpitation, fatigue and weakness, weight loss, increased appetite, thyroid enlargement and exopthalmos, (2) elevation of serum thyroxine (T4), and (3) increased radioactive iodine uptake.

The diagnosis of Hashimoto's thyroiditis was based on the follwoing criteria: (1) hypothyroidism, enlarged, firm or hard thyroid gland, (2) decreased serum T4 and T3, (3) diffuse lymphocytic infiltration, often with a considerable admixture of plasma cells by the examination of fine needle aspiration cytology or biopsy, (4) decreased RAIU.

The clinical diagnosis of LT-SRH was based on the following criteria: (1) painless, non-tender goiter, (2) elevated serum T4, T3, and (3) decreased RAIU. The diagnosis of SAT was based on the following criteria: (1) painful, tender thyroid gland, (2) fever, (3) elevation of the erythrocyte sedimentation rate (ESR), (4) normal or elevcated serum T4, T3, and (5) decreased RAIU.

The clinical diagnosis of post-partum thyroiditis was based on (1) a non-tender diffuse enlarged thyroid gland, puffy face, (2) normal or decreased serum T4, (3) history of recent delivery, and (4) decreased RAIU.

Thyroid hormone concentrations were measured by radioimmunoassay (RIA) with commercially available kits and T4 by Tetrabead-^125^ from Abbott.

The serum thyroid stimulating hormone (TSH) was measured by immunoradiometric assay with the TSH Riabead Kit. Thyrotrophin binding inhibitor immunoglobulins (TBII) was measured utilizing the radioreceptor assay method of Shewring and Smith^[@b1-kjim-2-1-112-19]^. Radioidine uptake was measured at 2 and 24 hours after oral administration of 50 *μ*Ci^131^I.

RESULTS
=======

Laboratory findings in 10 normal controls, 1 male and 9 females, show serum T4 10.1±1.6 *μ*g/dl, serum TSH 1.87±0.94 *μ*IU/ml, TBII 3.0±3.0%, and I^131^ uptake at 2 hours 8.0±3.0% and at 24 hours 23.0±8.0% respectively ([Table 6](#t6-kjim-2-1-112-19){ref-type="table"}).

In 30 patients with Graves' disease, 8 males and 22 females, serum T4, TSH, and TBII were 19.2±1.8 *μ*g/dl, 0.76±0.06 *μ*IU/mL, and 44.9±8.7% respecitively. I^131^ uptake at 2 hours was 44.7±7.36% and at 24 hours 57.5±6.95% ([Table 1](#t1-kjim-2-1-112-19){ref-type="table"}, [6](#t6-kjim-2-1-112-19){ref-type="table"}). In 13 patients with Hashimoto's thyroiditis, 2 males and 11 females, serum T4, TSH, and TBII were 3.56±4.37 *μ*g/dl, 24.05±14.20 *μ*IU/mL, 8.69±8.06% respectively. I^131^ uptake shows 2 hour levels of 9.9 ± 7.2% and 24 hour levels of 20.9 ± 15.1% ([Table 2](#t2-kjim-2-1-112-19){ref-type="table"}, [6](#t6-kjim-2-1-112-19){ref-type="table"}) ([Fig. 1](#f1-kjim-2-1-112-19){ref-type="fig"}, [2](#f2-kjim-2-1-112-19){ref-type="fig"}).

Laboratory data in 20 patients with LT-SRH, 1 male and 19 females, shows serum T4 10.57±3.74 *μ*g/dl, TSH 1.73±0.95 *μ*IU/mL, TBII 7.63±2.32% respectively, and I^131^ uptake shows 2 hours levels of 4.7±2.9%, and 24 hours levels of 12.8±9.6% ([Table 3](#t3-kjim-2-1-112-19){ref-type="table"}, [6](#t6-kjim-2-1-112-19){ref-type="table"}). In postpartum thyroiditis, serum T4, TSH, and TBII were 7.18±3.53 *μ*g/dl, 1.74±1.14 *μ*IU/mL, 3.33±1.16% respecitively, while I^131^ uptake at 2 hours was 3.66±1.15% and at 24 hours was 10.33±7.64% ([Table 4](#t4-kjim-2-1-112-19){ref-type="table"}, [6](#t6-kjim-2-1-112-19){ref-type="table"}).

In subacute thyroiditis, 7 patients all female, serum T4, TSH, and TBII were 10.47±2.56 *μ*g/dl, 1.46±0.65 *μ*IU/mL, 2.67±2.33% respectively. I^131^ uptake levels at 2 hours were 6.86±3.13% and at 24 hours 16.0±12.0% respectively ([Table 5](#t5-kjim-2-1-112-19){ref-type="table"}, [6](#t6-kjim-2-1-112-19){ref-type="table"}).

DISCUSSION
==========

There is almost universal agreement that thyroid autoantibodies exist and belong to the IgG class of immunoglobins. These are antibodies against components of the thyroid plasma membrane, possibly including the TSH receptor. These immunoglobulins are thought to bind to their complementary antigenic regions on the plasma membrane and activate adenylate cyclase, thereby initiating a chain of reactions that leads to thyroid growth, increased vascularity, and hypersecretion of hormone.

The recent development of a radioreceptor assay for thyrotrophin has made it possible to detect immunoglobulins that inhibit the binding of thyrotropin to its receptor in patients with autoimmune thyroid disease^[@b2-kjim-2-1-112-19]^.

Although these immunoglobulins have been principally detected in patients with Graves' disease^[@b3-kjim-2-1-112-19]^, they have also been found in a small proportion of hypothyroid patients with Hashimoto's thyroiditis^[@b2-kjim-2-1-112-19]--[@b10-kjim-2-1-112-19]^. These immunoglobulins, originally called thyroid-stimulating immunoglobulins by Smith and Hall^[@b3-kjim-2-1-112-19]^, are more appropriately termed thyrotrophin-binding inhibitor immunoglobulins^[@b4-kjim-2-1-112-19]^ and are now considered to be antibodies to portions of the thyroid plasma membranes, including the thyrotrophin receptor^[@b3-kjim-2-1-112-19]^.

Radioreceptor techniques are employed to demonstrate that IgG is capable of inhibiting the binding of ^125^I-labeled bovine TSH to specific binding sites on the humane or porcine thyroid membrane.

The present study shows that thyrotrophin inhibitor immunoglobulin levels are significantly elevated in all 30 patients with untreated Graves' disease ([Table 1](#t1-kjim-2-1-112-19){ref-type="table"}, [6](#t6-kjim-2-1-112-19){ref-type="table"}). TBII activity was detected in 110 of 132 patients (83.3%) with untreated Graves' disease by Cho et al.^[@b11-kjim-2-1-112-19]^. In 9 cases of untreated Graves' disease, TBII activities ranged from 14--76 %, and were abnormally high in all cases when compared with 0.82% TBII activity in the normal controls by Kim et al.^[@b12-kjim-2-1-112-19]^.

In the present study, the mean serum TBII activities were 8.69±8.06% in Hashimoto's thyroiditis and 7.63±2.32% in lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (LT-SRH) ([Fig. 1](#f1-kjim-2-1-112-19){ref-type="fig"}, [2](#f2-kjim-2-1-112-19){ref-type="fig"}).

LT-SRH is characterized by a painless, non-tender goiter, transient hyperthyroidism, decreased thyroid radioactive iodine uptake and focal or diffuse lymphocytic infiltration on biopsy ([Table 3](#t3-kjim-2-1-112-19){ref-type="table"}, [6](#t6-kjim-2-1-112-19){ref-type="table"}).

LT-SRH has heen classified as a variant of subacute thyroiditis (SAT), because the clinical course of each is so similar^[@b13-kjim-2-1-112-19],[@b14-kjim-2-1-112-19]^. However, Dorfman et al.^[@b15-kjim-2-1-112-19]^ and Nikolai et al.^[@b16-kjim-2-1-112-19]^ have reported that LT-SRH was a similar form of the chronic lymphocitic thyroiditis (CLT), on the basis of the findings of positive thyroid auto-antibodies and lymphocytic infiltration on biopsy specimen. So far, LT-SRH has been known as an autimmune thyroiditis. The TBII activity findings of our studies on Hashimoto's thyroiditis and LT-SRH, suggest that those diseases were a similar form of the disease from an immunological basis. The clinical course of LT-SRH has not been certain until now. Nikolai et al.^[@b16-kjim-2-1-112-19]^ observed 54 patients with a history of LT-SRH over a 1 to 15 year period follow-up. 23 patients (42.6 %) were found to have a goiter after returning to normal thyroid hormone levels and persistent lymphocytic infiltration was noted on biopsy specimen. 5.6% of the patients showed permanent hypothyroidism while 32% of them had persistent antithyroid antibodies and 11% of the patients experienced recurrence. These finding suggest that LT-SRH may be as a persistent and progressive disease as CLT with recurrent episodes. Thus the develpment of goiter and thyroid failure may be a eventual progression. Gorman et al.^[@b17-kjim-2-1-112-19]^ pointed out the lack of oxyphilic change, as a suggestive histologic difference from CLT, but Nikolai et al.^[@b18-kjim-2-1-112-19]^ were against this finding by the observation of focal oxyphilic changes in the biopsy specimens of LT-SRH. One can not conclusively confirm a diagnosis of LT-SRH by only fine needle aspiration cytology of the thyroid gland ^[@b19-kjim-2-1-112-19],[@b20-kjim-2-1-112-19]^ but we noted numerous lymphocytes in 20 patients of the LT-SRH group.

The TBII acitivities in subacute thyroiditis (SAT) were 2.67±2.33%, and were very low when compared with 3.0±3.0% in the normal control values in this study ([Table 5](#t5-kjim-2-1-112-19){ref-type="table"}, [6](#t6-kjim-2-1-112-19){ref-type="table"}).

These findings suggested that the etiology of SAT is rather than a classical autoimmune thyroiditis but of viral origin.

Volp'e et al.^[@b21-kjim-2-1-112-19]^ have described four functional stages of SAT. In the first stage, acute inflammation causes the release of preformed stores of thyroid hormones to the inflamed thyroid gland. The patients show signs of clinical hyperthyroidism, and thyroid RAIU is absent or quite low.

In the second stage, over a period of a few weeks, serum levels of thyroid hormones decline to normal and clinical evidence of hyperthyroidism ceases. In the third stage, serum thyroid hormone values decline to the hypothyroid level, serum TSH rises above normal levels, RAIU rises to normal or increased levels, and the patients may be clinically hypothyroid. The fourth stage is characterized by a return of all thyroid fuctions to normal.

The TBII acitivities in postpartum thyroiditis of this study were 3.33±1.16%, and were similar values compared with 3.0±3.0% or normal control ([Table 4](#t4-kjim-2-1-112-19){ref-type="table"}, [6](#t6-kjim-2-1-112-19){ref-type="table"}). Even though the TBII activities were almost equal between postpartum and subacute thyroiditis, but disease entity of these is quite different on the aspect of autoimmune basis.

Amino and co-workers^[@b22-kjim-2-1-112-19],[@b23-kjim-2-1-112-19]^ reported cases of transient postpartum hypothyroidism with positive antithyroid antibodies. Nikolai et al.^[@b24-kjim-2-1-112-19],[@b25-kjim-2-1-112-19]^, as well as Hamburger^[@b26-kjim-2-1-112-19]^, report an unusually high frequency of postpartum silent thyroiditis patiensts in the population. About half of the Amino group women with silent thyroiditis had episodes within 6 months of pregnancy. Fine needle biopsy in the thyrotoxic phase showed lymphocytic thyroiditis^[@b27-kjim-2-1-112-19]^ and needle biopsy showed focal involution of epithelium without pseudogranulomas^[@b28-kjim-2-1-112-19],[@b32-kjim-2-1-112-19]^. The occurrence of silent thyroiditis in the postpartum period indirectly suggests an autoimmune process. Moreover, antithyroid antibody titers fall during pregnancy and rebound at postpartum^[@b33-kjim-2-1-112-19]^. A reduction of goitrous hypothyroidism during pregnancy has been reported^[@b34-kjim-2-1-112-19]^. Patients with autoimmune thyroiditis, K-cells, and antithyroid antibodies increased after delivery^[@b35-kjim-2-1-112-19]^. These findings indirectly support a possible autoimmune etiology for silent postpartum thyroiditis, involving on antibody-dependent cell mediated cytotoxic process.

![TBII activities in the normal control and in patients with Graves' disease, Hashimoto's thyroiditis, lymphocytic thyroiditis with spontaneously resolving hyperthyroidism, postpartum thyroiditis and subacute thyroiditis.](kjim-2-1-112-19f1){#f1-kjim-2-1-112-19}

![TBII activities and serum T4 values (mean) in patients with Graves' disease, Hashimoto's thyroiditis, lymphocytic thyroiditis with spontaneously resolving hyperthyroidism, postpartum thyroiditis, subacute thyroiditis and normal controls.](kjim-2-1-112-19f2){#f2-kjim-2-1-112-19}

###### 

Clinical and Laboratory Findings in Patients with Graves' Disease

  Patient No. (n=13)   Age/Sex    Serum thyroxine (*μ*g/dl)   Serum thyrotrophin (*μ*IU/ml)   TBII (%)    RAIU (%)    
  -------------------- ---------- --------------------------- ------------------------------- ----------- ----------- ----
  1                    33/M       14.2                        0.60                            58          58          52
  2                    33/F       16.2                        0.73                            44          65          69
  3                    22/F       16.2                        0.68                            70          42          63
  4                    49/M       22.9                        0.65                            51          22          44
  5                    26/F       24.0                        0.75                            40          69          47
  6                    40/M       14.0                        0.50                            22          24          47
  7                    33/F       20.2                        0.75                            21          34          44
  8                    20/M       23.4                        0.90                            64          70          72
  9                    43/F       19.6                        0.66                            23          52          52
  10                   17/F       14.3                        1.15                            17          66          51
  11                   39/F       24.0                        1.0                             77          40          75
  12                   28/M       19.0                        0.75                            40          20          40
  13                   48/M       2.1.7                       0.88                            74          48          66
  14                   32/F       14.4                        0.64                            23          21          38
  15                   33/F       22.3                        0.76                            22          45          65
  16                   49/F       16.5                        0.91                            95          45          65
  17                   29/F       18.0                        0.77                            82          51          86
  18                   46/F       12.7                        1.06                            31          30          50
  19                   33/F       24.0                        0.60                            85          25          62
  20                   64/F       24.0                        1.23                            53          40          47
  21                   59/F       24.0                        0.79                            63          21          11
  22                   51/M       23.3                        0.98                            48          26          25
  23                   36/F       24.0                        1.03                            14          53          77
  24                   60/F       24.0                        0.92                            22          97          78
  25                   22/F       10.1                        0.73                            21          44          57
  26                   24/F       24.0                        0.63                            34          67          93
  27                   46/F       24.0                        0.69                            32          55          91
  28                   33/F       10.6                        0.62                            38          41          64
  29                   17/F       10.7                        0.79                            22          14          40
  30                   35/M       23.1                        0.76                            63          69          65
  Mean±S.D.            19.2±1.8   0.76±0.06                   44.9±8.7                        44.7±7.36   57.5±6.95   

###### 

Clinical and Laboratory Findings in Patients with Hashimoto's Thyroiditis

  Patient No. (n=20)   Age/Sex       Serum thyroxine (*μ*g/dl)   Serum thyrotrophin (*μ*IU/ml)   TBII (%)    RAIU (%)      
  -------------------- ------------- --------------------------- ------------------------------- ----------- ------------- ----
  1                    24/F          3.5                         60.0                            0           16            35
  2                    54/F          6.7                         7.34                            0           8             10
  3                    57/F          4.8                         44.43                           11          1.4           4
  4                    33/F          4.4                         42.0                            10          13            23
  5                    23/F          4.8                         45.16                           7           27            44
  6                    31/F          11.5                        5.34                            22          5             17
  7                    60/F          1.4                         60.0                            0           4             4
  8                    39/F          8.1                         1.36                            1           5             10
  9                    37/F          8.1                         0.77                            0           7             27
  10                   32/F          8.0                         4.09                            7           11            39
  11                   49/M          8.9                         33.8                            48          5             13
  12                   38/F          9.4                         7.28                            0           19            42
  13                   30/F          8.5                         1.19                            7           8             4
  Mean ± S. D.         3.56 ± 4.37   24.0 ± 23.7                 8.7 ± 13.5                      9.9 ± 7.2   20.9 ± 15.1   

###### 

Clinical and Laboratory Findings in Patients with Lymphocytic Thyroiditis with Spontaneously Resolving Hyperthyroidism

  Patient No. (n=20)   Age/Sex      Serum thyroxine (*μ*g/dl)   Serum thyrotrophin (*μ*IU/ml)   TBII (%)    RAIU (%)      
  -------------------- ------------ --------------------------- ------------------------------- ----------- ------------- ----
  1                    52/F         2.9                         2.2                             0           4             8
  2                    45/F         11.2                        2.28                            6           3             6
  3                    60/F         10.5                        1.16                            8           3             6
  4                    53/F         3.5                         0.78                            0           7             14
  5                    26/F         6.9                         0.91                            0           3             33
  6                    24/F         9.3                         1.81                            9           6             22
  7                    63/F         10.5                        1.12                            7           4             10
  8                    22/F         9.1                         1.52                            5           5             9
  9                    45/F         12.5                        1.78                            8           5             19
  10                   26/F         10.0                        0.82                            10          3             1
  11                   36/F         14.0                        4.77                            2           8             26
  12                   24/F         7.5                         1.63                            6           4             11
  13                   53/F         9.4                         1.8                             12          9             22
  14                   33/F         13.1                        0.71                            8           1             1
  15                   29/F         8.6                         1.97                            5           2             6
  16                   32/F         17.7                        1.43                            10          1             1
  17                   32/F         15.8                        0.87                            9           1             1
  18                   42/F         8.6                         1.34                            2           4             8
  19                   26/F         11.6                        2.22                            7           4             12
  20                   32/F         8.2                         1.73                            8           12            23
  Mean ± S. D.         10.0 ± 3.6   1.73 ± 0.95                 7.63 ± 2.32                     4.7 ± 2.9   12.8 ± 9.56   

###### 

Clinical and Laboratory Findings in Patients with Postpartum Thyroiditis

  Patient No. (n=5)   Age/Sex       Serum thyroxine (*μ*g/dl)   Serum thyrotrophin (*μ*IU/ml)   TBII (%)      RAIU (%)      
  ------------------- ------------- --------------------------- ------------------------------- ------------- ------------- ----
  1                   27/F          9.4                         1.9                             0             5             17
  2                   29/F          9.8                         0.52                            2             3             2
  3                   31/F          4.0                         60.0                            4             37            52
  4                   25/F          2.7                         60.0                            0             51            90
  5                   31/F          10.0                        2.79                            4             3             12
  Mean ± S. D.        7.18 ± 3.53   1.74 ± 1.14                 3.33 ± 1.16                     3.66 ± 1.15   10.33 ± 7.6   

###### 

Clinical and Laboratory Findings in Patients with Subacute Thyroiditis

  Patient No. (n=7)   Age/Sex        Serum thyroxine (*μ*g/dl)   Serum thyrotrophin (*μ*IU/ml)   TBII (%)      RAIU (%)      
  ------------------- -------------- --------------------------- ------------------------------- ------------- ------------- ----
  1                   44/F           8.9                         1.4                             0             8             19
  2                   35/F           9.3                         1.68                            0             7             19
  3                   48/F           7.4                         1.49                            1             10            15
  4                   26/F           10.8                        1.44                            3             9             35
  5                   43/F           13.4                        2.68                            4             9             22
  6                   61/F           14.4                        0.89                            0             3             1
  7                   31/F           9.1                         0.68                            0             2             1
  Mean ± S. D.        10.47 ± 2.56   1.46 ± 0.65                 2.67 ± 2.33                     6.86 ± 3.13   16.0 ± 12.0   

###### 

Clinical and Laboratory Data for Normal Control, Graves' Disease, and Various Types of Thyroiditis

  Group                     No. of patients   Sex   Age (yrs)   Total T4 (*μ*g/dl)   TSH (*μ*IU/ml)   TBII (%)        RAIU (%)                    
  ------------------------- ----------------- ----- ----------- -------------------- ---------------- --------------- ------------- ------------- --------------
  Normal control            10                1     9           28 ± 17              10.1 ± 1.6       1.87 ± 0.94     3.0 ± 3.0     8.0 ± 3.0     23.0 ± 8.0
  Graves' disease           30                8     22          38 ± 12              19.2 ± 1.8       0.76 ± 0.06     44.9 ± 8.7    44.7 ± 7.36   57.5 ± 6.95
  Hashimoto's thyroiditis   13                2     11          37 ± 11              3.56 ± 4.37      24.05 ± 14.20   8.69 ± 8.06   9.9 ± 7.2     20.9 ± 15.1
  LT with SRH               20                1     19          38 ± 13              10.57 ± 3.74     1.73 ± 0.95     7.63 ± 2.32   4.7 ± 2.9     12.8 ± 9.6
  Postpartum thyroiditis    5                 (−)   5           29 ± 3               7.18 ± 3.53      1.74 ± 1.14     3.33 ± 1.16   3.66 ± 1.15   10.33 ± 7.64
  Subacute thyroiditis      7                 (−)   7           41 ± 12              10.47 ± 2.56     1.46 ± 0.65     2.67 ± 2.33   6.86 ± 3.13   16.0 ± 12.0

Mean ± S.D.
